View
Page
Northland also published a note this morning: "ValiRx continues to progress its two lead programmes. VAL201’s Phase 1/2 trial is moving into its expansion phase with the inclusion of additional clinical trial centres. To date, no drug related significant adverse events have been reported. VAL401 is close to commencing its clinical programme. The trial will take place in Georgia, with sites, investigators and facilities now confirmed."
Latest from the Community...
Latest from the Community...
Latest from the Community...